World-leading business angel syndicate investing in early-stage Scottish life sciences and technology companies.
The seed round was led by Blackfinch Ventures to support global growth and commercial adoption.
"This investment marks a significant step forward as we continue pioneering new applications for magnetic sensing. With the support of our investors, we are expanding our team, advancing our technology, and bringing our solutions closer to widespread adoption."
The investment round was led by Archangels with participation from Dr Yusuf Hamied, British Business Investments, and seed investors.
"Our DPI has the potential to become the simplest, most convenient single-dose, disposable inhaler on the market, revolutionising the delivery of critical drugs, without the cost and environmental impact of existing devices."
The funding will increase clinical capacity and support the delivery of Phase I trials for novel medicines.
"BDD is an excellent example of an ambitious and innovative Scottish life science company with global reach. Its patented timed-release technology, alongside world-class clinical trial services offering, created a compelling proposition for the pharma industry. Building on a successful 18 months after the challenges of the pandemic, the company is well poised to pursue its growth strategy. We’re excited by what the future holds for BDD and looking forward to supporting Carol and the team."
The investment round was led by Archangels to help the life science firm advance its cell analysis platform.
"We are uniquely positioned in harnessing the power of consumer electronics technology to meet the emerging, complex needs of the bioprocess industry. On the back of a very successful year for Cytomos, this new funding will now allow us to scale up our engagement with industry partners. We truly believe that, through our CDS technology, we offer a powerful platform which will help the scientific community bring novel therapies to market faster and radically reduce costs by making better informed, game-changing decisions a lot earlier."
The funding round was led by Archangels to support product development and US commercialisation.
"Bioliberty has developed a highly effective solution for helping patients with hand weakness, with the potential to improve the quality of life for millions worldwide. We believe its technology has far-reaching benefits beyond this first application, providing the business with an excellent opportunity to grow quickly from its base here in Scotland. Archangels is excited to be supporting the team as they finalise what we hope will be the first of many products and start scaling up their sales activity."
